#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA813408	B	Compound was tested for the inhibition of subtilisin		3	ALA1127999	single protein format	Scientific Literature
2.	ALA813409	B	Inhibitory activity against subtilisin		1	ALA1125161	single protein format	Scientific Literature
3.	ALA813410	B	Ratio of the kinetic constants (ki X 10e3) versus Ki was reported		1	ALA1125161	single protein format	Scientific Literature
4.	ALA813411	B	Ratio of the kinetic constants kH versus ki was reported		1	ALA1125161	single protein format	Scientific Literature
5.	ALA813412	B	The ratio (ki + kH)/ki (turnover ratio) was determined using ultimate activity assay		1	ALA1125161	single protein format	Scientific Literature
6.	ALA814093	B	Inhibitory activity against subtilisin		1	ALA1125161	single protein format	Scientific Literature
7.	ALA814094	B	Inhibitory activity against subtilisin		1	ALA1125161	single protein format	Scientific Literature
8.	ALA814095	B	Inhibitory activity against subtilisin		1	ALA1125161	single protein format	Scientific Literature
9.	ALA3887820	B	AlphaLISA Assay: An in-vitro AlphaLISA assay (Perkin Elmer) was developed in order to quantitate the level of PCSK9 secreted into the cell culture media following compound treatment. To detect and measure PCSK9 protein an in-house generated anti-PCSK9 antibody was coupled to AlphaLISA acceptor beads by an external vendor (PerkinElmer) and a second internally developed anti-PCSK9 antibody with an epiptope distinct from that of the acceptor beads was biotinylated in house. Streptavidin coated-donor beads (Perkin Elmer) are also included in the assay mixture which then binds the biotinylated anti-PCSK9 antibody and in the presence of PCSK9 this donor complex and acceptor beads are brought into close proximity. Upon excitation of the donor beads at 680 nm singlet oxygen molecules are released that trigger an energy transfer cascade within the acceptor beads resolving as a single peak of light emitted at 615 nm. The ability of compound to modulate PCSK9 protein levels in conditioned media by AlphaLISA was assessed in the human hepatocellular carcinoma cell line Huh7, stably over-expressing human PCSK9.		41	ALA3886461	assay format	BindingDB Database
10.	ALA3887821	B	Cell Free Assay: In order to eliminate the permeability barrier inherent to the WT7 and SCHH cell-based assays a cell-free system was also established to access compound activity. A sequence containing the full length human PCSK9 (NCBI reference identifier, NM-174936.3, where coding sequence start annotated at position 363) along with 84 additional 3⿲ nucleotides, comprising a V5 tag and polylinkinker followed by an in frame modified firefly luciferase reporter (corresponding to nucleotide positions 283-1929 of pGL3, Gen Bank reference identifier JN542721.1) was cloned into the pT7CFE1 expression vector (ThermoScientific). The construct was then in-vitro transcribed using the MEGAscript T7 Kit (Life Technologies) and RNA subsequently purified incorporating the MEGAclear Kit (Life Technologies) according to manufacturer's protocols. HeLa cell lysates were prepared following the protocols described by Mikami (reference is Cell-Free Protein Synthesis Systems with Extracts from Cultured Human Cells, S. Mikami, T. Kobayashi and H. Imataka; from Methods in Molecular Biology, vol. 607, pages 43-52, Y. Endo et al. (eds.), Humana Press, 2010) with the following modifications.		33	ALA3886461	cell-based format	BindingDB Database
11.	ALA4221922	B	Inhibition of PCSK9 (unknown origin) at 1.25 uM	Homo sapiens	2	ALA4219125	single protein format	Scientific Literature
12.	ALA4221923	B	Inhibition of recombinant PCSK9 (unknown origin) expressed in human HepG2 cells assessed as increase in LDLR expression levels relative to control	Homo sapiens	1	ALA4219125	cell-based format	Scientific Literature
13.	ALA4221924	B	Inhibition of recombinant PCSK9 (unknown origin) expressed in human HepG2 cells assessed as increase in LDL uptake at 10 uM after 16 hrs by fluorescence assay	Homo sapiens	1	ALA4219125	cell-based format	Scientific Literature
14.	ALA4221925	B	Inhibition of recombinant PCSK9 (unknown origin) expressed in human HepG2 cells assessed as increase in LDL uptake at 1.25 uM after 16 hrs by fluorescence assay	Homo sapiens	1	ALA4219125	cell-based format	Scientific Literature
15.	ALA4221926	B	Inhibition of recombinant PCSK9 (unknown origin) expressed in human HepG2 cells assessed as increase in LDL uptake at 0.31 uM after 16 hrs by fluorescence assay	Homo sapiens	1	ALA4219125	cell-based format	Scientific Literature
16.	ALA4221927	B	Inhibition of PCSK9 in human HepG2 cells assessed as increase in LDLR expression levels at 1.6 uM relative to control	Homo sapiens	1	ALA4219125	cell-based format	Scientific Literature
17.	ALA4221928	B	Inhibition of PCSK9 in human HepG2 cells assessed as increase in uptake of fluorescent Dil-LDL at 0.37 uM relative to control	Homo sapiens	2	ALA4219125	cell-based format	Scientific Literature
18.	ALA4221929	B	Inhibition of PCSK9 in human HepG2 cells assessed as increase in uptake of fluorescent Dil-LDL at 1.5 uM relative to control	Homo sapiens	2	ALA4219125	cell-based format	Scientific Literature
19.	ALA4221930	B	Inhibition of PCSK9 (unknown origin) expressed in human HepG2 cells assessed as increase in LDL uptake at 100 uM	Homo sapiens	1	ALA4219125	cell-based format	Scientific Literature
20.	ALA4221931	A	Activation of PCSK9 (unknown origin) expressed in human HepG2 cells assessed as decrease in LDL uptake at 25 uM	Homo sapiens	1	ALA4219125	cell-based format	Scientific Literature